The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Therapeutic Potential of Spirooxindoles as Antiviral Agents
Open accessAbstract
Antiviral therapeutics with profiles of high potency, low resistance, panserotype, and low toxicity remain challenging, and obtaining such agents continues to be an active area of therapeutic development. Due to their unique three-dimensional structural features, spirooxindoles have been identified as privileged chemotypes for antiviral drug development. Among them, spiro-pyrazolopyridone oxindoles have been recently reported as potent inhibitors of dengue virus NS4B, leading to the discovery of an orally bioavailable preclinical candidate (R)-44 with excellent in vivo efficacy in a dengue viremia mouse model. This review highlights recent advances in the development of biologically active spirooxindoles for their antiviral potential, primarily focusing on the structure-activity relationships (SARs) and modes of action, as well as future directions to achieve more potent analogues toward a viable antiviral therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Galliford, C. V., & Scheidt, K. A. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701342 · Cited by 2,429
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Escape from Flatland 2: complexity and promiscuity
Lovering, F. (2013) · MedChemComm · doi:10.1039/c2md20347b · Cited by 1,444
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., et al. (2010) · Science · doi:10.1126/science.1193225 · Cited by 1,206
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
The use of spirocyclic scaffolds in drug discovery
Zheng, Y., Tice, C. M., & Singh, S. B. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.081 · Cited by 1,036
Spirooxindoles: Promising scaffolds for anticancer agents
Yu, B., Yu, D.-Q., & Liu, H.-M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.056 · Cited by 867
Flexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Enantioselective methodologies for the synthesis of spiro compounds
Rios, R. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15156h · Cited by 781
Recent Advances in Asymmetric Organocatalytic Construction of 3,3′‐Spirocyclic Oxindoles
Hong, L., & Wang, R. (2013) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201200808 · Cited by 718
Strategies for the enantioselective synthesis of spirooxindoles
Ball-Jones, N. R., Badillo, J. J., & Franz, A. K. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob25184a · Cited by 692
Structure-based design of potent non-peptide MDM2 inhibitors
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657
Current and Future Therapies for Hepatitis C Virus Infection
Liang, T. J., & Ghany, M. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1213651 · Cited by 490
DeVincenzo, J., Lambkin-Williams, R., Wilkinson, T., Cehelsky, J., Nochur, S., Walsh, E., Meyers, R., Gollob, J., & Vaishnaw, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912186107 · Cited by 442
Immunopathological mechanisms in dengue and dengue hemorrhagic fever
Green, S., & Rothman, A. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000244047.31135.fa · Cited by 389
Antivirals and antiviral strategies
Clercq, E. D. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro975 · Cited by 370
Ten years of dengue drug discovery: Progress and prospects
Lim, S. P., Wang, Q.-Y., Noble, C. G., Chen, Y.-L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.013 · Cited by 350
Self-citationA Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese Adults
Tricou, V., Minh, N. N., Van, T. P., Lee, S. J., Farrar, J., Wills, B., Tran, H. T., & Simmons, C. P. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000785 · Cited by 329
Jiang, T., Kuhen, K., Wolff, K. C., Yin, H., Bieza, K., Caldwell, J. S., Bursulaya, B. D., Wu, T. Y., & He, Y. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.073 · Cited by 301
Structure-based drug design to augment hit discovery
Kalyaanamoorthy, S., & Chen, Y.-P. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.07.006 · Cited by 296
Link, J. O., Taylor, J. G., Xu, L., Mitchell, M., Guo, H., Liu, H., Kato, D., Kirschberg, T., Sun, J., Squires, N., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401499g · Cited by 295
Nguyen, N. M., Tran, C. N. B., Phung, L. K., Duong, K. T. H., Huynh, H. L. A., Farrar, J., Nguyen, Q. T. H., Tran, H. T., Nguyen, C. V. V., Merson, L., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis470 · Cited by 293
Zhao, Y., Yu, S., Sun, W., Liu, L., Lu, J., McEachern, D., Shargary, S., Bernard, D., Li, X., Zhao, T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4005708 · Cited by 290
Active-learning strategies in computer-assisted drug discovery
Reker, D., & Schneider, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.004 · Cited by 261
Low, J. G., Sung, C., Wijaya, L., Wei, Y., Rathore, A. P. S., Watanabe, S., Tan, B. H., Toh, L., Chua, L. T., Hou, Y., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70730-3 · Cited by 253
New developments in anti-HIV chemotherapy
De Clercq, E. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00089-3 · Cited by 248
Strategic priorities for respiratory syncytial virus (RSV) vaccine development
Anderson, L. J., Dormitzer, P. R., Nokes, D. J., Rappuoli, R., Roca, A., & Graham, B. S. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.11.106 · Cited by 242
Fragment-based lead discovery grows up
Baker, M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3926 · Cited by 214
Tam, D. T. H., Ngoc, T. V., Tien, N. T. H., Kieu, N. T. T., Thuy, T. T. T., Thanh, L. T. C., Tam, C. T., Truong, N. T., Dung, N. T., Qui, P. T., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis655 · Cited by 208
From Structure to Function: New Insights into Hepatitis C Virus RNA Replication
Appel, N., Schaller, T., Penin, F., & Bartenschlager, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r500026200 · Cited by 202
Ginès, P., Wong, F., Watson, H., Milutinovic, S., Ruiz del Arbol, L., & Olteanu, D. (2008) · Hepatology · doi:10.1002/hep.22293 · Cited by 193
HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1
Schröfelbauer, B., Hakata, Y., & Landau, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610167104 · Cited by 187
Molecular mechanism of respiratory syncytial virus fusion inhibitors
Battles, M. B., Langedijk, J. P., Furmanova-Hollenstein, P., Chaiwatpongsakorn, S., Costello, H. M., Kwanten, L., Vranckx, L., Vink, P., Jaensch, S., Jonckers, T. H. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1982 · Cited by 173
Whitehorn, J., Châu, N. V. V., Khanh, L. P., Kien, D. T. H., Quyen, N. T. H., Tran, N. T. T., Hang, N. T., Truong, N. T., Tai, L. T. H., Huong, N. T. C., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ949 · Cited by 165
Soupart, A., Gross, P. A., Legros, J., Diaeresis]ldi, S. A. A. A., Annane, D., Heshmati, H. M., & Decaux, G. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00160106 · Cited by 142
Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research
Pouliot, M., & Jeanmart, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00361 · Cited by 132
Evolutions in fragment-based drug design: the deconstruction–reconstruction approach
Chen, H., Zhou, X., Wang, A., Zheng, Y., Gao, Y., & Zhou, J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.015 · Cited by 123
Self-citationBelema, M., & Meanwell, N. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500335h · Cited by 112
Discovery of Dengue Virus NS4B Inhibitors
Wang, Q.-Y., Dong, H., Zou, B., Karuna, R., Wan, K. F., Zou, J., Susila, A., Yip, A., Shan, C., Yeo, K. L., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00855-15 · Cited by 106
Self-citationFiltering promiscuous compounds in early drug discovery: is it a good idea?
Senger, M. R., Fraga, C. A. M., Dantas, R. F., & Silva, F. P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.004 · Cited by 95
Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.023 · Cited by 94
Self-citationYe, N., Chen, C.-H., Chen, T., Song, Z., He, J., Huan, X., Song, S.-S., Liu, Q., Chen, Y., Ding, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301825t · Cited by 91
Self-citationGrowing PAINS in Academic Drug Discovery
Whitty, A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.44 · Cited by 88
Ding, C., Zhang, Y., Chen, H., Yang, Z., Wild, C., Ye, N., Ester, C. D., Xiong, A., White, M. A., Shen, Q., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401248x · Cited by 84
Self-citationSmall molecule inhibitors of the hepatitis C virus-encoded NS5A protein
Belda, O., & Targett‐Adams, P. (2012) · Virus Research · doi:10.1016/j.virusres.2012.09.007 · Cited by 81
Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
Belema, M., Lopez, O. D., Bender, J. A., Romine, J. L., Laurent, D. R. S., Langley, D. R., Lemm, J. A., O’Boyle, D. R., Sun, J.-H., Wang, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401793m · Cited by 75
Lead Optimization of Spiropyrazolopyridones: A New and Potent Class of Dengue Virus Inhibitors
Zou, B., Chan, W. L., Ding, M., Leong, S. Y., Nilar, S., Seah, P. G., Liu, W., Karuna, R., Blasco, F., Yip, A., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500521r · Cited by 74
Self-citationCruciferous phytoalexins: antiproliferative effects in T-Jurkat leukemic cells
Pilátová, M. B., Šarišský, M., Kutschy, P., Miroššay, A., Mezencev, R., Čurillová, Z., Suchý, M., Monde, K., Mirossay, L., & Mojžíš, J. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.09.003 · Cited by 72
Identification and Characterization of Small Molecules as Potent and Specific EPAC2 Antagonists
Chen, H., Tsalkova, T. N., Chepurny, O. G., Mei, F. C., Holz, G. G., Cheng, X., & Zhou, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3014162 · Cited by 68
Self-citationHighlights in Antiviral Drug Research: Antivirals at the Horizon
Clercq, E. D. (2012) · Medicinal Research Reviews · doi:10.1002/med.21256 · Cited by 65
A Cutting‐Edge View on the Current State of Antiviral Drug Development
Clercq, E. D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21281 · Cited by 57
Potent oxindole based human β3 adrenergic receptor agonists
Stevens, F. C., Bloomquist, W. E., Borel, A. G., Cohen, M. L., Droste, C. A., Heiman, M. L., Kriauciunas, A., Sall, D. J., Tinsley, F. C., & Jesudason, C. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.011 · Cited by 49
Nishizawa, M., Kamata, M., Katsumata, R., & Aida, Y. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6058-6067.2000 · Cited by 42
Ye, N., Zhu, Y., Chen, H., Liu, Z., Mei, F. C., Wild, C., Chen, H., Cheng, X., & Zhou, J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00635 · Cited by 40
Self-citationCombrink, K. D., Gülgeze, H. B., Thuring, J. W., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.065 · Cited by 40
Hagiwara, K., Murakami, T., Xue, G., Shimizu, Y., Takeda, E., Hashimoto, Y., Honda, K., Kondoh, Y., Osada, H., Tsunetsugu‐Yokota, Y., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.107 · Cited by 34
Antiviral Agents: Structural Basis of Action and Rational Design
Menéndez‐Arias, L., & Gago, F. (2013) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-6552-8_20 · Cited by 32
Treatment of HIV infection with once-daily regimens
Permpalung, N., Putcharoen, O., Avihingsanon, A., & Ruxrungtham, K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.729040 · Cited by 31
Indolin-2-one p38α inhibitors I: Design, profiling and crystallographic binding mode
Eastwood, P. R., González, J., Gómez, E., Vidal, B., Caturla, F., Roca, R., Balagué, C., Orellana, A., & Domínguez, M. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.05.114 · Cited by 30
Chen, H., Wang, C. Z., Ding, C., Wild, C., Copits, B. A., Swanson, G. T., Johnson, K. M., & Zhou, J. (2012) · ChemMedChem · doi:10.1002/cmdc.201200554 · Cited by 28
Self-citationPerspectives on antiviral drug development
Wainberg, M. A. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.09.003 · Cited by 19
Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV
Achenbach, C. J., Scarsi, K. K., & Murphy, R. L. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0006-9 · Cited by 15
Cited by
Worldwide Research Trends on Medicinal Plants
Salmerón-Manzano, E., Garrido-Cardenas, J. A., & Manzano-Agugliaro, F. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103376 · Cited by 546
Catalytic asymmetric synthesis of spirooxindoles: recent developments
Mei, G.-J., & Shi, F. (2018) · Chemical Communications · doi:10.1039/c8cc02364f · Cited by 467
Stereoselective synthesis and applications of spirocyclic oxindoles
Boddy, A. J., & Bull, J. A. (2021) · Organic Chemistry Frontiers · doi:10.1039/d0qo01085e · Cited by 362
An overview of spirooxindole as a promising scaffold for novel drug discovery
Zhou, L.-M., Qu, R.-Y., & Yang, G.-F. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1733526 · Cited by 316
An overview of functional nanoparticles as novel emerging antiviral therapeutic agents
Chen, L., & Liang, J. (2020) · Materials Science and Engineering: C · doi:10.1016/j.msec.2020.110924 · Cited by 255
Metadata
- Authors
- Ye, N., Chen, H., Wold, E. A., Shi, P.-Y., & Zhou, J.
- Venue
- ACS Infectious Diseases
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-05-05
- Volume
- 2
- Issue
- 6
- Pages
- 382-392
- ISSN
- 2373-8227 (ISSN-L)
- OpenAlex
- W2345105659
- Cited by
- 493
- References
- 64
- FWCI
- 20.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.